$7.8 billion. That’s the topline on Lilly’s bid for Centessa Pharmaceuticals — and the structure is the story.
Lilly is paying $38 per share in cash, aggregating to roughly $6.3 billion. Each Centessa shareholder also gets one non-tradable contingent value right worth up to $9 per share, payable only if specific FDA approvals land. Add it up and the deal tops out at $7.8 billion. That CVR is the buyer’s hedge — Lilly only pays the full price if the science works.
What Lilly is actually buying: a pipeline of orexin receptor 2 agonists led by cleminorexton, currently in Phase IIa trials across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The class targets the same wakefulness biology that Takeda’s been chasing for years, and Takeda has been the unchallenged leader in orexin agonism. Lilly just put a $7.8 billion stake in the ground next door.
The math gets interesting when you remember Lilly already owns the GLP-1 category. Adding a sleep-wake franchise gives them a second underserved-but-massive market — narcolepsy alone is estimated at 200,000 diagnosed US patients with no curative therapy.
The kicker: Centessa is incorporated in England, so the deal needs court sanction under English law in addition to shareholder approval. Translation: the path to closing is longer than a typical US biotech buyout, and the CVR clock doesn’t start until after.
Closes Q3 2026.
— Diana Kowalski